Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.56 |
| ▸ | LIPE | Q05469 | 1/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.48 |
| ▸ | RBP4 | P02753 | 2/20 | 0.48 |
| ▸ | PRCP | P42785 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | GBA1 | P04062 | 1/20 | 0.45 |
| ▸ | SFRP1 | Q8N474 | 1/20 | 0.45 |
| ▸ | HTR6 | P50406 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3224467 | 0.88 | HSD11B1 (0.57) | MEN1KMT2ARBP4MAPT | |
| SCHEMBL3205508 | 0.85 | KMT2A (0.54) | MEN1KMT2AEPHX2RBP4MAPT | |
| SCHEMBL3209386 | 0.84 | HSD11B1 (0.55) | MEN1KMT2ARBP4MAPT | |
| SCHEMBL3215762 | 0.84 | GPR183 (0.53) | MEN1KMT2ARBP4MAPTSFRP1 | |
| SCHEMBL3221289 | 0.82 | HSD11B1 (0.64) | MEN1KMT2ARBP4 | |
| SCHEMBL3201836 | 0.82 | LMNA (0.60) | MEN1KMT2ARBP4MAPT | |
| SCHEMBL3219555 | 0.80 | HSD11B1 (0.64) | MEN1KMT2ARBP4MAPTHTR6 | |
| SCHEMBL2171815 | 0.80 | EPHX2 (0.61) | MEN1KMT2ALIPEEPHX2EPHX1 | |
| SCHEMBL3224261 | 0.79 | KMT2A (0.70) | MEN1KMT2ARBP4 | |
| SCHEMBL3210171 | 0.78 | RBP4 (0.61) | KMT2ARBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | MEN1 1354/4885KMT2A 1609/4885LIPE 883/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | MEN1 1687/4885KMT2A 1591/4885LIPE 842/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.